Wikerholmen T, Taule E, Rigg E, Berle B, Saettem M, Sarnow K
Clin Exp Metastasis. 2025; 42(2):12.
PMID: 39856383
PMC: 11761981.
DOI: 10.1007/s10585-025-10328-3.
Kenton E, Zoellner S, Nelson L
Ment Health Clin. 2023; 13(4):193-195.
PMID: 37860588
PMC: 10583255.
DOI: 10.9740/mhc.2023.08.193.
Fornaro M, Caiazza C, Solini N, De Prisco M, Billeci M, Vannini M
Mol Psychiatry. 2023; 28(9):3648-3660.
PMID: 37821573
DOI: 10.1038/s41380-023-02266-x.
Fehsel K, Schwanke K, Kappel B, Fahimi E, Meisenzahl-Lechner E, Esser C
J Psychopharmacol. 2022; 36(2):191-201.
PMID: 34979820
PMC: 8847763.
DOI: 10.1177/02698811211055811.
Foster D, Bryant Z, Conn P
Behav Brain Res. 2021; 405:113201.
PMID: 33647377
PMC: 8006961.
DOI: 10.1016/j.bbr.2021.113201.
Positive allosteric modulation of M and M muscarinic receptors as potential therapeutic treatments for schizophrenia.
Yohn S, Conn P
Neuropharmacology. 2017; 136(Pt C):438-448.
PMID: 28893562
PMC: 5844786.
DOI: 10.1016/j.neuropharm.2017.09.012.
New strategic insights into managing fungal biofilms.
Borghi E, Morace G, Borgo F, Rajendran R, Sherry L, Nile C
Front Microbiol. 2015; 6:1077.
PMID: 26500623
PMC: 4594024.
DOI: 10.3389/fmicb.2015.01077.
Different methods, different results--how do available methods link a patient's anticholinergic load with adverse outcomes?.
Mayer T, Haefeli W, Seidling H
Eur J Clin Pharmacol. 2015; 71(11):1299-314.
PMID: 26350641
DOI: 10.1007/s00228-015-1932-x.
Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex.
Gigout S, Wierschke S, Dehnicke C, Deisz R
Naunyn Schmiedebergs Arch Pharmacol. 2015; 388(5):487-96.
PMID: 25592256
DOI: 10.1007/s00210-014-1080-3.
The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.
Watt M, Rorick-Kehn L, Shaw D, Knitowski K, Quets A, Chesterfield A
Neuropsychopharmacology. 2013; 38(13):2717-26.
PMID: 23907402
PMC: 3828543.
DOI: 10.1038/npp.2013.186.
Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.
Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R
CNS Drugs. 2013; 27(7):545-72.
PMID: 23821039
DOI: 10.1007/s40263-013-0079-5.
Novel designer receptors to probe GPCR signaling and physiology.
Wess J, Nakajima K, Jain S
Trends Pharmacol Sci. 2013; 34(7):385-92.
PMID: 23769625
PMC: 3758874.
DOI: 10.1016/j.tips.2013.04.006.
Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia.
de Oliveira G, Gomes P, de Araujo F, Vasconcelos S, Junior H, de Sousa F
Metab Brain Dis. 2012; 28(1):53-9.
PMID: 23095989
DOI: 10.1007/s11011-012-9345-3.
Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice.
Singer P, Yee B
Pharmacol Biochem Behav. 2012; 101(1):107-14.
PMID: 22210488
PMC: 3587654.
DOI: 10.1016/j.pbb.2011.12.010.
Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.
Thomsen M, Wess J, Fulton B, Fink-Jensen A, Caine S
Psychopharmacology (Berl). 2009; 208(3):401-16.
PMID: 20013114
PMC: 3895331.
DOI: 10.1007/s00213-009-1740-z.
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
Lieberman J, Bymaster F, Meltzer H, Deutch A, Duncan G, Marx C
Pharmacol Rev. 2008; 60(3):358-403.
PMID: 18922967
PMC: 4821196.
DOI: 10.1124/pr.107.00107.
The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats.
Prus A, Pehrson A, Philibin S, Wood J, Vunck S, Porter J
Psychopharmacology (Berl). 2008; 203(2):295-301.
PMID: 18685832
DOI: 10.1007/s00213-008-1262-0.
Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice.
Thomsen M, Wortwein G, Fink-Jensen A, Woldbye D, Wess J, Caine S
Psychopharmacology (Berl). 2007; 192(1):97-110.
PMID: 17310388
DOI: 10.1007/s00213-006-0682-y.
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?.
Davies M, Compton-Toth B, Hufeisen S, Meltzer H, Roth B
Psychopharmacology (Berl). 2005; 178(4):451-60.
PMID: 15765260
DOI: 10.1007/s00213-004-2017-1.
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
Weiner D, Meltzer H, Veinbergs I, Donohue E, Spalding T, Smith T
Psychopharmacology (Berl). 2004; 177(1-2):207-16.
PMID: 15258717
DOI: 10.1007/s00213-004-1940-5.